CCL2 and acute kidney injury: Treatment with rosuvastatin decreased IL-6, MCP-1, and TNF-α mRNA levels by 50% (P < 0.01), 49% (P < 0.01), and 45% (P < 0.01), respectively, compared with the CI-AKI group.